JPWO2019226514A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019226514A5 JPWO2019226514A5 JP2020564841A JP2020564841A JPWO2019226514A5 JP WO2019226514 A5 JPWO2019226514 A5 JP WO2019226514A5 JP 2020564841 A JP2020564841 A JP 2020564841A JP 2020564841 A JP2020564841 A JP 2020564841A JP WO2019226514 A5 JPWO2019226514 A5 JP WO2019226514A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- gene
- adenocarcinoma
- treatment
- expression level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000011510 cancer Diseases 0.000 claims 15
- 230000004547 gene signature Effects 0.000 claims 11
- 238000009169 immunotherapy Methods 0.000 claims 6
- 239000012472 biological sample Substances 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 4
- 208000009956 Adenocarcinoma Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 210000004027 cells Anatomy 0.000 claims 3
- 210000001519 tissues Anatomy 0.000 claims 3
- 101700044891 GNLY Proteins 0.000 claims 2
- 102100018517 GNLY Human genes 0.000 claims 2
- 102100004383 GZMA Human genes 0.000 claims 2
- 101710014159 GZMA Proteins 0.000 claims 2
- 102100004391 GZMB Human genes 0.000 claims 2
- 101710014161 GZMB Proteins 0.000 claims 2
- 102100004385 GZMH Human genes 0.000 claims 2
- 101710014271 GZMH Proteins 0.000 claims 2
- 102100016384 HAVCR2 Human genes 0.000 claims 2
- 101710004393 HAVCR2 Proteins 0.000 claims 2
- 108060004270 LAG3 Proteins 0.000 claims 2
- 102100017213 LAG3 Human genes 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 108020004999 Messenger RNA Proteins 0.000 claims 2
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims 2
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 101710039933 PFN1 Proteins 0.000 claims 2
- 102100014927 PRF1 Human genes 0.000 claims 2
- 101700016865 PRF1 Proteins 0.000 claims 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 2
- 101710018203 TPRP-F1 Proteins 0.000 claims 2
- 101710018080 ThorAB25_04690 Proteins 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 2
- 229940121650 immune-checkpoint protein inhibitors Drugs 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 229920002106 messenger RNA Polymers 0.000 claims 2
- 230000001629 suppression Effects 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 206010000880 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 206010001197 Adenocarcinoma of the cervix Diseases 0.000 claims 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims 1
- 206010061424 Anal cancer Diseases 0.000 claims 1
- 102100009333 BTLA Human genes 0.000 claims 1
- 101700047069 BTLA Proteins 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 210000004369 Blood Anatomy 0.000 claims 1
- 210000004556 Brain Anatomy 0.000 claims 1
- 210000000481 Breast Anatomy 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 102100000166 CD226 Human genes 0.000 claims 1
- 101700022117 CD226 Proteins 0.000 claims 1
- 101700056583 CD27 Proteins 0.000 claims 1
- 102100019459 CD27 Human genes 0.000 claims 1
- 102100019456 CD276 Human genes 0.000 claims 1
- 101700015421 CD276 Proteins 0.000 claims 1
- 102100019461 CD28 Human genes 0.000 claims 1
- 101700033362 CD28 Proteins 0.000 claims 1
- 102100013137 CD40 Human genes 0.000 claims 1
- 101710040446 CD40 Proteins 0.000 claims 1
- 102100005830 CD70 Human genes 0.000 claims 1
- 101700017377 CD70 Proteins 0.000 claims 1
- 101710026045 CD96 Proteins 0.000 claims 1
- 102100014435 CD96 Human genes 0.000 claims 1
- 102100005310 CTLA4 Human genes 0.000 claims 1
- 101700054183 CTLA4 Proteins 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 1
- 206010073251 Clear cell renal cell carcinoma Diseases 0.000 claims 1
- 206010012818 Diffuse large B-cell lymphoma Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 102100003900 GEM Human genes 0.000 claims 1
- 108060003143 GEM Proteins 0.000 claims 1
- 206010017758 Gastric cancer Diseases 0.000 claims 1
- 210000004392 Genitalia Anatomy 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010073071 Hepatocellular carcinoma Diseases 0.000 claims 1
- -1 ICOS Proteins 0.000 claims 1
- 102100017339 KLRC1 Human genes 0.000 claims 1
- 101710036388 KLRC1 Proteins 0.000 claims 1
- 102100012223 KLRK1 Human genes 0.000 claims 1
- 101710036390 KLRK1 Proteins 0.000 claims 1
- 210000003734 Kidney Anatomy 0.000 claims 1
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 102100014650 MICA Human genes 0.000 claims 1
- 101700060941 MICA Proteins 0.000 claims 1
- 206010025650 Malignant melanoma Diseases 0.000 claims 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims 1
- 206010025310 Other lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 239000012270 PD-1 inhibitor Substances 0.000 claims 1
- 229940121655 PD-1 inhibitors Drugs 0.000 claims 1
- 239000012271 PD-L1 inhibitor Substances 0.000 claims 1
- 229940121656 PD-L1 inhibitors Drugs 0.000 claims 1
- 239000012272 PD-L2 inhibitor Substances 0.000 claims 1
- 229940121654 PD-L2 inhibitors Drugs 0.000 claims 1
- 102100019764 PDCD1 Human genes 0.000 claims 1
- 208000007312 Paraganglioma Diseases 0.000 claims 1
- 206010061332 Paraganglion neoplasm Diseases 0.000 claims 1
- 210000002381 Plasma Anatomy 0.000 claims 1
- 206010038019 Rectal adenocarcinoma Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 108060007796 SPATA2 Proteins 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000000587 Small Cell Lung Carcinoma Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 206010041866 Squamous cell carcinoma of the vagina Diseases 0.000 claims 1
- 102100006047 TIGIT Human genes 0.000 claims 1
- 101700052319 TIGIT Proteins 0.000 claims 1
- 102100008790 TNFRSF14 Human genes 0.000 claims 1
- 101710038603 TNFRSF18 Proteins 0.000 claims 1
- 102100003096 TNFRSF18 Human genes 0.000 claims 1
- 101710040448 TNFRSF4 Proteins 0.000 claims 1
- 102100013135 TNFRSF4 Human genes 0.000 claims 1
- 102100009537 TNFRSF9 Human genes 0.000 claims 1
- 101710040535 TNFRSF9 Proteins 0.000 claims 1
- 206010046766 Uterine cancer Diseases 0.000 claims 1
- 102100015314 VSIR Human genes 0.000 claims 1
- 101710036075 VSIR Proteins 0.000 claims 1
- 101700068327 VTCN1 Proteins 0.000 claims 1
- 102100014952 VTCN1 Human genes 0.000 claims 1
- 101700040525 aceA Proteins 0.000 claims 1
- 101710026144 acu-3 Proteins 0.000 claims 1
- 201000002454 adrenal cortex cancer Diseases 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 230000003042 antagnostic Effects 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 201000011165 anus cancer Diseases 0.000 claims 1
- 201000009036 biliary tract cancer Diseases 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 201000009030 carcinoma Diseases 0.000 claims 1
- 238000002659 cell therapy Methods 0.000 claims 1
- 201000006662 cervical adenocarcinoma Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 201000006612 cervical squamous cell carcinoma Diseases 0.000 claims 1
- 201000010897 colon adenocarcinoma Diseases 0.000 claims 1
- 201000011231 colorectal cancer Diseases 0.000 claims 1
- 201000008325 diseases of cellular proliferation Diseases 0.000 claims 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 101710004278 icl Proteins 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000010445 mica Substances 0.000 claims 1
- 229910052618 mica group Inorganic materials 0.000 claims 1
- 230000000955 neuroendocrine Effects 0.000 claims 1
- 201000010302 ovarian serous cystadenocarcinoma Diseases 0.000 claims 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims 1
- 201000010198 papillary carcinoma Diseases 0.000 claims 1
- 201000005825 prostate adenocarcinoma Diseases 0.000 claims 1
- 201000001281 rectum adenocarcinoma Diseases 0.000 claims 1
- 230000001850 reproductive Effects 0.000 claims 1
- 201000003708 skin melanoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 230000002381 testicular Effects 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 201000001384 vagina sarcoma Diseases 0.000 claims 1
Claims (12)
- 処置の選択を必要とする癌患者の処置の選択を補助する方法であって、
癌患者から得られた生物学的試料中の遺伝子シグネチャーの遺伝子のそれぞれの発現レベルを決定することを含み、
遺伝子シグネチャーは、GZMA、GZMB、GZMH、PRF1及びGNLYを含み、
遺伝子シグネチャーの遺伝子の発現レベルの変化により処置のための患者が特定される、方法。 - 治療による処置に応答する可能性が高い癌を有する被験体の特定を補助する方法であって、被験体から得られた生物学的試料中の遺伝子シグネチャーの遺伝子のそれぞれの発現レベルを決定することを含み、
遺伝子シグネチャーは、GZMA、GZMB、GZMH、PRF1及びGNLYを含み、
遺伝子シグネチャーの遺伝子の発現レベルの変化により治療による処置に応答する可能性が高い被験体が特定される、方法。 - 前記遺伝子シグネチャーの遺伝子の発現レベルの上昇がある場合、前記癌患者は活性化免疫療法の処置を施す対象として特定され、前記遺伝子シグネチャーの遺伝子の発現レベルの減少がある場合、前記癌患者は抑制免疫療法を施す対象として特定される、請求項1に記載の方法。
- 前記遺伝子シグネチャーの遺伝子の発現レベルの上昇がある場合、前記癌を有する被験体は活性化免疫療法による処置に応答する可能性が高いとして特定され、前記遺伝子シグネチャーの遺伝子の発現レベルの減少がある場合、前記癌を有する被験体は抑制免疫療法による処置に応答する可能性が高いとして特定される、請求項2に記載の方法。
- 前記患者又は被験体に前記遺伝子シグネチャーの遺伝子の発現レベルの変化の結果を通知する工程をさらに含む、請求項1~4のいずれか1項に記載の方法。
- 前記活性化免疫療法が、
(a) GITR、OX40、TIM3、LAG3、KIR、CD28、CD137、CD27、CD40、CD70、CD276、ICOS、HVEM、NKG2D、NKG2A、MICA、2B4、又は41BBアゴニスト、又はこれらの組み合わせ;
(b)チェックポイント阻害剤、好ましくは、チェックポイント阻害剤はPD-1阻害剤、PD-L1阻害剤、PD-L2阻害剤、又はこれらの組み合わせである;
(c)キメラ抗原受容体T細胞治療;又は
(d)これらの組み合わせ
を含む、請求項3又は4に記載の方法。 - 前記抑制免疫療法が、CTLA4、PD-1軸、TIM3、BTLA、VISTA、LAG3、B7H4、CD96、TIGIT、又はCD226アンタゴニスト、又はこれらの組み合わせを含む、請求項3又は4に記載の方法。
- 前記癌が、副腎皮質癌、膀胱尿路上皮癌、***浸潤癌、頸部扁平上皮癌、子宮頸部腺癌、胆管癌、結腸腺癌、リンパ系新生物びまん性大型B細胞リンパ腫、食道癌、多形性神経膠芽細胞腫、頭頸部扁平上皮癌、嫌色素性腎癌、腎明細胞癌、腎乳頭細胞癌、急性骨髄性白血病、脳低悪性度神経膠腫、肝細胞癌、肺腺癌、肺扁平上皮癌、中皮腫、卵巣漿液性嚢胞腺癌、膵臓腺癌、クロム親和性細胞腫、傍神経節腫、前立腺腺癌、直腸腺癌、肉腫、皮膚黒色腫、胃腺癌、精巣生殖細胞腫瘍、甲状腺癌、胸腺腫、子宮癌肉腫、ぶどう膜黒色腫腫である、請求項1~7のいずれか1項に記載の方法。
- 前記癌が、乳癌、肺癌、リンパ腫、黒色腫、肝臓癌、結腸直腸癌、卵巣癌、膀胱癌、腎臓癌、又は胃癌である、請求項1~7のいずれか1項に記載の方法。
- 前記癌が、神経内分泌癌、非小細胞肺癌(NSCLC)、小細胞肺癌、甲状腺癌、子宮内膜癌、胆道癌、食道癌、肛門癌、唾液腺癌、外陰癌、又は子宮頚癌である、請求項1~7のいずれか1に記載の方法。
- 前記患者又は被験体からの生物学的試料中の遺伝子の発現が、mRNAを測定することによって決定され、好ましくは、前記患者又は被験体からの生物学的試料中の遺伝子の発現が、
(a)血漿;
(b)組織;又は
(c)FFPE組織
におけるmRNAを測定することによって決定される、請求項1~10のいずれか1項に記載の方法。 - 前記生物学的試料が
(a)腫瘍組織又は
(b)血液
である、請求項1~8のいずれか1項に記載の方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2024034926A JP2024053048A (ja) | 2018-05-21 | 2024-03-07 | 分子遺伝子シグネチャーとその使用方法 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862674285P | 2018-05-21 | 2018-05-21 | |
US62/674,285 | 2018-05-21 | ||
US201862747853P | 2018-10-19 | 2018-10-19 | |
US62/747,853 | 2018-10-19 | ||
PCT/US2019/033052 WO2019226514A2 (en) | 2018-05-21 | 2019-05-20 | Molecular gene signatures and methods of using same |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2024034926A Division JP2024053048A (ja) | 2018-05-21 | 2024-03-07 | 分子遺伝子シグネチャーとその使用方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021524744A JP2021524744A (ja) | 2021-09-16 |
JPWO2019226514A5 true JPWO2019226514A5 (ja) | 2022-05-30 |
Family
ID=67002367
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020564841A Pending JP2021524744A (ja) | 2018-05-21 | 2019-05-20 | 分子遺伝子シグネチャーとその使用方法 |
JP2024034926A Pending JP2024053048A (ja) | 2018-05-21 | 2024-03-07 | 分子遺伝子シグネチャーとその使用方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2024034926A Pending JP2024053048A (ja) | 2018-05-21 | 2024-03-07 | 分子遺伝子シグネチャーとその使用方法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20210363590A1 (ja) |
EP (1) | EP3797173A2 (ja) |
JP (2) | JP2021524744A (ja) |
CN (1) | CN112771177A (ja) |
AU (1) | AU2019275404A1 (ja) |
CA (1) | CA3100200A1 (ja) |
WO (1) | WO2019226514A2 (ja) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2849965B2 (es) * | 2020-02-21 | 2023-11-17 | Fundacion Para La Investig E Innovacion Biosanitaria De Asturias Finba Ispa | Metodo para predecir o pronosticar la respuesta al tratamiento del cancer |
WO2021228888A1 (en) * | 2020-05-12 | 2021-11-18 | Asylia Diagnostics | Biomarkers for hyperprogressive disease and therapy response after immunotherapy |
US20230250173A1 (en) * | 2020-07-01 | 2023-08-10 | Pfizer Inc. | Biomarkers for pd-1 axis binding antagonist therapy |
WO2022012420A1 (zh) * | 2020-07-17 | 2022-01-20 | 信达生物制药(苏州)有限公司 | 一种核苷酸组合及其应用 |
US20220143220A1 (en) * | 2020-10-19 | 2022-05-12 | Washington University | Compositions and methods for modulating myc target protein 1 |
TW202241469A (zh) * | 2021-02-20 | 2022-11-01 | 美商凱特製藥公司 | 免疫療法 |
WO2022211620A1 (en) * | 2021-04-01 | 2022-10-06 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Cd4/il-2 biomarker. |
CN114231623B (zh) * | 2021-10-14 | 2023-09-08 | 福建中医药大学 | Palmdelphin在制备人结直肠癌检测及治疗产品中的应用 |
WO2023070121A1 (en) * | 2021-10-22 | 2023-04-27 | The Wistar Institute Of Anatomy And Biology | Compositions and methods for treatment of mic60 depleted cancers and metastasis |
CN113913507A (zh) * | 2021-10-29 | 2022-01-11 | 温州医科大学附属第一医院 | Ccl3蛋白作为评估非酒精性脂肪性肝病炎症水平及疾病进展的生物标志物的应用 |
WO2023092119A2 (en) * | 2021-11-22 | 2023-05-25 | Ludwig Institute For Cancer Research Ltd | Methods for predicting responsiveness to a cancer therapy |
WO2023155021A1 (en) * | 2022-02-18 | 2023-08-24 | London Health Sciences Centre Research Inc. | Immune classification tool for determining survival outcomes in cancer |
CN115896290B (zh) * | 2022-11-29 | 2023-11-24 | 中国人民解放军海军军医大学 | Trim21基因检测在肿瘤诊断、治疗选择和预后评估中的应用 |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
DE69025946T2 (de) | 1989-09-08 | 1996-10-17 | Univ Johns Hopkins | Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
IL105914A0 (en) | 1992-06-04 | 1993-10-20 | Univ California | Methods and compositions for in vivo gene therapy |
GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
DE69428764T2 (de) | 1993-12-24 | 2002-06-20 | Merck Patent Gmbh | Immunokonjugate |
IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
US5679683A (en) | 1994-01-25 | 1997-10-21 | Warner-Lambert Company | Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
US5910486A (en) | 1994-09-06 | 1999-06-08 | Uab Research Foundation | Methods for modulating protein function in cells using, intracellular antibody homologues |
US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
CA2216796C (en) | 1995-03-30 | 2003-09-02 | Pfizer Inc. | Quinazoline derivatives |
GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
GB9508537D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
AU6267896A (en) | 1995-06-07 | 1996-12-30 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth oftumors |
KR100437582B1 (ko) | 1995-07-06 | 2004-12-17 | 노파르티스 아게 | 피롤로피리미딘및그들의제조방법 |
US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
CA2249446C (en) | 1996-04-12 | 2008-06-17 | Warner-Lambert Company | Irreversible inhibitors of tyrosine kinases |
WO1998002434A1 (en) | 1996-07-13 | 1998-01-22 | Glaxo Group Limited | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
WO1998050038A1 (en) | 1997-05-06 | 1998-11-12 | American Cyanamid Company | Use of quinazoline compounds for the treatment of polycystic kidney disease |
ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
WO1999024037A1 (en) | 1997-11-06 | 1999-05-20 | American Cyanamid Company | Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps |
PT1131304E (pt) | 1998-11-19 | 2003-04-30 | Warner Lambert Co | N-¬4-(3-cloro-4-fluoro-fenilamino)-7-(3-morfolin-4-il-propoxi)-quinazolin-6-il|-acrilamida um inibidor irreversivel de tirosino quinases |
US7473767B2 (en) | 2001-07-03 | 2009-01-06 | The Institute For Systems Biology | Methods for detection and quantification of analytes in complex mixtures |
WO2003086467A1 (en) | 2002-04-08 | 2003-10-23 | Smithkline Beecham Corporation | Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor |
CN1852974A (zh) * | 2003-06-09 | 2006-10-25 | 密歇根大学董事会 | 用于治疗和诊断癌症的组合物和方法 |
WO2005071419A2 (en) * | 2004-01-16 | 2005-08-04 | Ipsogen | Protein expression profiling and breast cancer prognosis |
KR101419711B1 (ko) * | 2005-09-08 | 2014-07-17 | 가부시키가이샤 메디넷 | 항원제시세포의 활성화 처리방법 |
WO2007076132A2 (en) | 2005-12-23 | 2007-07-05 | Nanostring Technologies, Inc. | Compositions comprising oriented, immobilized macromolecules and methods for their preparation |
JP5537034B2 (ja) | 2005-12-23 | 2014-07-02 | ナノストリング テクノロジーズ,インコーポレーテッド | ナノレポーターならびにその作製方法および使用方法 |
US7941279B2 (en) | 2006-05-22 | 2011-05-10 | Nanostring Technologies, Inc. | Systems and methods for analyzing nanoreporters |
US20090076734A1 (en) * | 2007-03-22 | 2009-03-19 | Torres-Roca Javier F | Gene Signature for the Prediction of Radiation Therapy Response |
EP2155899A2 (en) | 2007-04-10 | 2010-02-24 | Nanostring Technologies, Inc. | Methods and computer systems for identifying target-specific sequences for use in nanoreporters |
CA2733609C (en) | 2008-08-14 | 2018-03-06 | Nanostring Technologies, Inc. | Stable nanoreporters |
WO2010076788A2 (en) * | 2008-12-29 | 2010-07-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods of predicting responsiveness to interferon treatment and treating hepatitis c infection |
EP3236264A3 (en) | 2009-10-13 | 2017-11-08 | Nanostring Technologies, Inc | Protein detection via nanoreporters |
WO2012129488A2 (en) * | 2011-03-23 | 2012-09-27 | Virginia Commonwealth University | Gene signatures associated with rejection or recurrence of cancer |
GB201217892D0 (en) | 2012-10-05 | 2012-11-21 | Virttu Biolog Ltd | Treatment of cancer |
SG11201502778TA (en) * | 2012-10-12 | 2015-05-28 | Agency Science Tech & Res | Method of prognosis and stratification of ovarian cancer |
EP3008209A2 (en) | 2013-06-14 | 2016-04-20 | Nanostring Technologies, Inc | Multiplexable tag-based reporter system |
WO2016044189A1 (en) * | 2014-09-15 | 2016-03-24 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonist and il-17 binding antagonists |
US20170298443A1 (en) * | 2014-09-25 | 2017-10-19 | Moffitt Genetics Corporation | Prognostic tumor biomarkers |
CA2968406A1 (en) * | 2014-12-09 | 2016-06-16 | Mark D. Ayers | System and methods for deriving gene signature biomarkers of response to pd-1 antagonists |
WO2016109546A2 (en) * | 2014-12-30 | 2016-07-07 | Genentech, Inc. | Methods and compositions for prognosis and treatment of cancers |
PT3294770T (pt) * | 2015-05-12 | 2020-12-04 | Hoffmann La Roche | Métodos terapêuticos e diagnósticos para o cancro |
CA2992492A1 (en) | 2015-07-17 | 2017-01-26 | Nanostring Technologies, Inc. | Simultaneous quantification of gene expression in a user-defined region of a cross-sectioned tissue |
WO2017096458A1 (en) * | 2015-12-07 | 2017-06-15 | Ontario Institute For Cancer Research (Oicr) | Immune gene signature predictive of anthracycline benefit |
WO2017216559A1 (en) * | 2016-06-14 | 2017-12-21 | Almac Diagnostics Limited | Predicting responsiveness to therapy in prostate cancer |
EP3622092A4 (en) * | 2017-05-11 | 2021-06-23 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS OF USE OF CD8 + TUMOR-INFILTRATING LYMPHOCYTE SUBTYPES AND GENE SIGNATURES THEREOF |
EP3775877A4 (en) * | 2018-04-13 | 2021-12-22 | X4 Pharmaceuticals, Inc. | CANCER SERUM BIOMARKERS AND METHOD OF USE THEREOF |
-
2019
- 2019-05-20 JP JP2020564841A patent/JP2021524744A/ja active Pending
- 2019-05-20 CA CA3100200A patent/CA3100200A1/en active Pending
- 2019-05-20 US US17/054,204 patent/US20210363590A1/en active Pending
- 2019-05-20 AU AU2019275404A patent/AU2019275404A1/en active Pending
- 2019-05-20 WO PCT/US2019/033052 patent/WO2019226514A2/en unknown
- 2019-05-20 EP EP19732785.1A patent/EP3797173A2/en active Pending
- 2019-05-20 CN CN201980048546.5A patent/CN112771177A/zh active Pending
-
2024
- 2024-03-07 JP JP2024034926A patent/JP2024053048A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Tu et al. | Assessment of the expression of the immune checkpoint molecules PD‐1, CTLA4, TIM‐3 and LAG‐3 across different cancers in relation to treatment response, tumor‐infiltrating immune cells and survival | |
Kato et al. | Analysis of circulating tumor DNA and clinical correlates in patients with esophageal, gastroesophageal junction, and gastric adenocarcinoma | |
Salem et al. | Landscape of tumor mutation load, mismatch repair deficiency, and PD-L1 expression in a large patient cohort of gastrointestinal cancers | |
Guibert et al. | Monitoring of KRAS-mutated ctDNA to discriminate pseudo-progression from true progression during anti-PD-1 treatment of lung adenocarcinoma | |
JPWO2019226514A5 (ja) | ||
Choueiri et al. | Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial | |
Kang et al. | Circulating cell-free DNA for metastatic cervical cancer detection, genotyping, and monitoring | |
Mak et al. | A patient-derived, pan-cancer EMT signature identifies global molecular alterations and immune target enrichment following epithelial-to-mesenchymal transition | |
Hernandez et al. | Expression of the antiapoptotic protein survivin in colon cancer | |
Nowicki et al. | Infiltration of CD8 T cells and expression of PD-1 and PD-L1 in synovial sarcoma | |
Chaudhry et al. | Resistance to chemotherapy and hormone therapy in endometrial cancer | |
AU2017267184A1 (en) | Method for assessing a prognosis and predicting the response of patients with malignant diseases to immunotherapy | |
Xu et al. | CXCR4 overexpression is correlated with poor prognosis in colorectal cancer | |
Zhu et al. | Clinical significance of programmed death ligand-1 (PD-L1) in colorectal serrated adenocarcinoma | |
Dietel | Molecular pathology: a requirement for precision medicine in cancer | |
Zhang et al. | Low expression of RBMS3 and SFRP1 are associated with poor prognosis in patients with gastric cancer | |
Liu et al. | Tumor suppressor gene mutations correlate with prognosis and immunotherapy benefit in hepatocellular carcinoma | |
Lin et al. | Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond | |
Mahmoudian et al. | Correlation between the immune checkpoints and EMT genes proposes potential prognostic and therapeutic targets in ESCC | |
Imai et al. | High expression of P-cadherin is significantly associated with poor prognosis in patients with non-small-cell lung cancer | |
Kwon et al. | Programmed death ligand-1 and MET co-expression is a poor prognostic factor in gastric cancers after resection | |
Li et al. | Follistatin-like 1 (FSTL1) is a prognostic biomarker and correlated with immune cell infiltration in gastric cancer | |
Gleeson et al. | Endoscopic ultrasound may be used to deliver gene expression signatures using digital mRNA detection methods to immunophenotype pancreatic ductal adenocarcinoma to facilitate personalized immunotherapy | |
Yao et al. | Pan-cancer biomarkers: changing the landscape of molecular testing | |
Zhang et al. | Establishment of the prognostic index of lung squamous cell carcinoma based on immunogenomic landscape analysis |